menu
    • menu

    Company profile for Eradivir

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Eradivir, founded in March 2020 by Dr. Philip S. Low, is advancing targeted small-molecule therapies that deliver payloads directly to diseased cells via high-specificity ligands. The founder has previously developed multiple FDA-approved molecules, including a radiotherapy drug for prostate cancer and an imaging agent for lung and ovarian cancers. Eradivir leverages this platform to tackle various diseases, with an initial fo...
    Eradivir, founded in March 2020 by Dr. Philip S. Low, is advancing targeted small-molecule therapies that deliver payloads directly to diseased cells via high-specificity ligands. The founder has previously developed multiple FDA-approved molecules, including a radiotherapy drug for prostate cancer and an imaging agent for lung and ovarian cancers. Eradivir leverages this platform to tackle various diseases, with an initial focus on influenza and other respiratory infections, while additional therapies for cancer, malaria, and sickle cell anemia are in clinical development.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    EradivirUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    West Lafayette, IN US
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://eradivir.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Eradivir to Deliver Oral Presentations on Influenza and RSV
    Eradivir to Deliver Oral Presentations on Influenza and RSV

    15 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260415404188/en/Eradivir-to-Deliver-Oral-Presentations-on-Influenza-and-RSV-at-ESCMID-Global-and-ICAR-2026

    BUSINESSWIRE
    15 Apr 2026
    Share Share
    Eradivir Announces Nomination of Its Development Candidate EV148
    Eradivir Announces Nomination of Its Development Candidate EV148

    12 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260212647199/en/Eradivir-Announces-the-Nomination-of-Its-Development-Candidate-EV148-for-the-Treatment-of-RSV

    BUSINESSWIRE
    12 Feb 2026
    Share Share
    Eradivir's EV25 Excels Result In Phase 2a Influenza Trial
    Eradivir's EV25 Excels Result In Phase 2a Influenza Trial

    15 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-15/eradivir-s-ev25-shows-promising-results-in-phase-2a-trial-for-the-treatment-of-influenza

    PHARMIWEB
    15 Oct 2025
    Share Share
    Eradivir Secures $10 Million In Private Financing
    Eradivir Secures $10 Million In Private Financing

    07 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-07/eradivir-secures-10-million-in-private-financing

    PHARMIWEB
    07 Oct 2025
    Share Share
    Eradivir to Present at 2025 BIO International Convention
    Eradivir to Present at 2025 BIO International Convention

    10 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250610772333/en/Eradivir-To-Present-At-2025-Biotechnology-Innovation-Organization-BIO-International-Convention

    BUSINESSWIRE
    10 Jun 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search